Miracor Medical Systems launches PiCSO Impulse System in Asia
“I’m impressed at how PiCSO supports my patients during PCI”
(Dr. Arif Al Nooryani, CEO, Head of Cardiac Center, Al Qassimi Hospital, Sharjah, UAE)
VIENNA, Austria, September 21, 2015 – Miracor Medical Systems (Miracor) announced today the first treatments of patients with the PiCSOAMI Impulse System in the United Arab Emirates (UAE), marking the launch of this novel therapy in Asia in cooperation with Medical Technology Est..
The first cases using the PiCSOAMI Impulse System have been performed by Dr. Arif Al Nooryani, CEO and Head of Cardiac Center and his team at Al Qassimi Hospital, the largest public hospital in Sharjah emirate and largest hospital under the umbrella of the Federal Ministry of Health in the UAE.
“We applied PiCSO therapy during complex PCI procedures, treating non-ST-elevation myocardial infarction patients,” said Dr. Arif Al Nooryani. “Directly following diagnostic angiography, we initiated PiCSO therapy for the duration of the complex stenting procedures to improve myocardial perfusion. I was impressed to see the immediate effect of PiCSO, as my patients did not experience chest pain, nor did we see ECG changes or signs of no-reflow phenomena, which can normally be expected during such procedures,” he continued. “This demonstrates the positive effects of PiCSO on myocardial perfusion. I now look forward to making this therapy available for our acute myocardial infarction patients at Al Qassimi Hospital.”
The procedures in the UAE were performed with the support of Access Medical LLC., a UAE-based medical devices distributor and sister company of Medical Technology Est., which is now co-operating with Miracor to launch the PiCSOAMI Impulse System also in the Kingdom of Saudi Arabia, Kuwait and Oman.
“The launch of PiCSO in Asia marks an important milestone in the ongoing commercialization of PiCSO worldwide,” says Lars Schiemanck, Managing Director of Miracor. “Integrating PiCSO therapy into regular PCI procedures without interrupting the workflow of the cath lab was made possible by the introduction of Miracor’s second generation device in 2014. This has been demonstrated in clinical use in Europe and greatly expands the potential use of PiCSO therapy. Our goal is to make this innovative therapy available to acute myocardial infarction patients worldwide.”